Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA

被引：1
|
作者：
Lisberg, A. [1 ]
Bornazyan, K. [1 ]
Madrigal, J. [1 ]
Bui, J. [1 ]
Carroll, J. [1 ]
Adame, C. [1 ]
Hunt, J. [1 ]
Lu, H. [1 ]
Noor, Z. [1 ]
Cummings, A. [1 ]
Goldman, J. W. [1 ]
Garon, E. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; anti-PD-1; therapy; Thyroid;
D O I：
10.1016/j.jtho.2017.11.097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-038
引用
收藏
页码：S2430 / S2430
页数：1
相关论文
共 42 条
  • [1] Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001
    Ahn, M. -J.
    Gandhi, L.
    Hamid, O.
    Hellmann, M. D.
    Garon, E. B.
    Ramalingam, S. S.
    Lubiniecki, G. M.
    Zhang, J.
    Piperdi, B.
    Hui, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [2] Patients (Pts) with advanced NSCLC from Korea treated with pembrolizumab (Pembro) in KEYNOTE-001
    Lee, J. -S.
    Lee, D. H.
    Piperdi, B.
    Zhang, J.
    Lubiniecki, G. M.
    Ahn, M. -J.
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [3] Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001
    Rochigneux, P.
    Lisberg, A.
    Garcia, A.
    Chretien, A. S.
    Fattori, S.
    Madroszyk, A.
    Tseng, A.
    Akingbemi, W.
    Gukasyan, J.
    Madrigal, J.
    Carroll, J.
    Noor, Z.
    Cummings, A.
    Olive, D.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S452 - S453
  • [4] Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab
    Ramalingam, Suresh
    Hui, Rina
    Gandhi, Leena
    Carcereny, Enric
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph P.
    Balmanoukian, Ani S.
    Leighl, Natasha
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Middleton, Gary W.
    Gubens, Matthew
    Hellmann, Matthew
    Soria, Jean-Charles
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S241 - S242
  • [5] Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).
    Hui, Rina
    Gandhi, Leena
    Costa, Enric Carcereny
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Leighl, Natasha B.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Middleton, Gary William
    Gubens, Matthew A.
    Hellmann, Matthew David
    Soria, Jean-Charles
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.
    Leigh, Natasha B.
    Hellmann, Matthew David
    Hui, Rina
    Costa, Enric Carcereny
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani Sarkis
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies
    Butler, M.
    Hamid, O.
    Ribas, A.
    Hodi, F. S.
    Walpole, E.
    Dauad, A.
    Arance, A.
    Brown, E.
    Hoeller, C.
    Mortier, L.
    Schachter, J.
    Long, J.
    Ebbinghaus, S.
    Ibrahim, N.
    Robert, C.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S123 - S123
  • [8] Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
    Lisberg, Aaron
    Tucker, D. Andrew
    Goldman, Jonathan W.
    Wolf, Brian
    Carroll, James
    Hardy, Ariana
    Morris, Karolyn
    Linares, Paulina
    Adame, Carlos
    Spiegel, Marshall
    Wells, Courtney
    Mckenzie, Jordan
    Ledezma, Blanca
    Mendenhall, Melody
    Abarca, Phillip
    Bornazyan, Krikor
    Hunt, Jamie
    Famenini, Sina
    Strunck, Jennifer
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1328 - S1328
  • [9] Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
    Lisberg, Aaron
    Tucker, D. Andrew
    Goldman, Jonathan W.
    Wolf, Brian
    Carroll, James
    Hardy, Ariana
    Morris, Karolyn
    Linares, Paulina
    Adame, Carlos
    Spiegel, Marshall L.
    Wells, Courtney
    McKenzie, Jordan
    Ledezma, Blanca
    Mendenhall, Melody
    Abarca, Phillip
    Bornazyan, Krikor
    Hunt, Jaime
    Moghadam, Nima
    Chong, Natalie
    Nameth, Danielle
    Marx, Caitlin
    Madrigal, John
    Vangala, Sitaram
    Shaverdian, Narek
    Elashoff, David
    Garon, Edward B.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (03) : 288 - 294
  • [10] Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
    Hamid, O.
    Robert, C.
    Daud, A.
    Hodi, F. S.
    Hwu, W. J.
    Kefford, R.
    Wolchok, J. D.
    Hersey, P.
    Joseph, R.
    Weber, J. S.
    Dronca, R.
    Mitchell, T. C.
    Patnaik, A.
    Zarour, H. M.
    Joshua, A. M.
    Zhao, Q.
    Jensen, E.
    Ahsan, S.
    Ibrahim, N.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 582 - 588
12345